Novo Nordisk: Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Read full article »
Novo Nordisk is a Denmark-based multinational pharmaceutical company that develops and commercializes diabetes care medications and devices for the healthcare industry.
Read more